Answers are grounded in this paper and cite their sources.
Evaluates treatment outcomes in follicular lymphoma, suggesting improved strategies for therapy sequences.
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma, with approximately 14,000 new diagnoses annually in the United States. Although FL has historically been considered incurable, front-line therapy can induce durable remissions. Nevertheless, up to 50% of patients require multiple lines of treatment [ 1 ]. Importantly, the efficacy of therapy diminishes with successive lines [ 1 ], underscoring the importance of strategic sequencing of treatments in the management of FL.
No takes yet. Share an insight, caveat, or question.
Sharp et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: